Redifferentiation of a BRAFK601E-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment

Thyroid ◽  
2019 ◽  
Vol 29 (5) ◽  
pp. 735-742 ◽  
Author(s):  
Sophie Leboulleux ◽  
Corinne Dupuy ◽  
Ludovic Lacroix ◽  
Marie Attard ◽  
Serena Grimaldi ◽  
...  
2018 ◽  
Vol 27 (3) ◽  
pp. 261-267 ◽  
Author(s):  
Masami Ohnishi ◽  
Chiaki Takagi ◽  
Hiroki Takahashi ◽  
Hiroshi Okuda ◽  
Miki Umeda

2010 ◽  
Vol 35 (7) ◽  
pp. 499-504 ◽  
Author(s):  
Dong Li ◽  
Zhaowei Meng ◽  
Guizhi Zhang ◽  
Tielian Yu ◽  
Jian Tan ◽  
...  

2020 ◽  
Vol V (I) ◽  
pp. 32-38
Author(s):  
Nida Javaid ◽  
Sana Asghar ◽  
Zainab Yasmeen

Among the endocrine malignancies, thyroid cancer is the most commonly occurring and increasing around the globe. Inspite of prognosis, about 5-10% people become victim of differentiated thyroid cancer. Cancer is basically uncontrolled division of cells. These rapidly developing cells become toxic for the body of patient once they start travelling from place to another because in such situation the early diagnosis even does not benefit while in case of localized cancer, chances of survival increase. In thyroid cancer, patient becomes aggressive abruptly with developing metastasis. In case of gene mutations, every patient got a different mutated gene from other against which several medicines have been under consideration. This review has been put together to overview the disease, its etiology, pathogenesis, and treatment methods.


Sign in / Sign up

Export Citation Format

Share Document